Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings
Article first published online: 4 OCT 2004
Copyright © 2004 Wiley-Liss, Inc.
Cytometry Part B: Clinical Cytometry
Volume 62B, Issue 1, pages 25–38, November 2004
How to Cite
Voskova, D., Schoch, C., Schnittger, S., Hiddemann, W., Haferlach, T. and Kern, W. (2004), Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry, 62B: 25–38. doi: 10.1002/cyto.b.20025
- Issue published online: 21 OCT 2004
- Article first published online: 4 OCT 2004
- Manuscript Accepted: 5 JUL 2004
- Manuscript Received: 4 MAR 2004
- acute myeloid leukemia;
- minimal residual disease;
- multiparameter flow cytometry;
- leukemia-associated aberrant immunophenotypes;
- prognostic factors
Multiparameter flow cytometry is increasingly used to monitor minimal residual disease in patients with acute myeloid leukemia to identify leukemic cells by leukemia-associated aberrant immunophenotypes (LAIPs). Changes in LAIPs during the course of the disease may be a limitation for this approach.
We analyzed 49 patients at diagnosis and relapse by flow cytometry, cytomorphology, cytogenetics, and molecular genetics.
In 37 patients (76%), at least one LAIP detectable at diagnosis was present at relapse; in 12 patients (24%), none of the original LAIPs were present in at least 1% of bone marrow cells. Three groups were identified: no change in LAIPs, partial changes in LAIPs, and complete change in LAIPs. There were significant differences across these groups with regard to changes in cytomorphology (11%, 40%, and 58% of all cases, respectively; P = 0.007), cytogenetics (15%, 20%, and 25%; not significant), and molecular genetics (18%, 0, and 86%; P = 0.002).
These data indicate that, in a subset of patients with acute myeloid leukemia, the disease is biologically different at relapse; therefore, monitoring of minimal residual disease is difficult to accomplish. In most patients with acute myeloid leukemia, multiparameter flow cytometry may be used to monitor minimal residual disease. © 2004 Wiley-Liss, Inc.